🟢 Goodrx is trading 11% up today after Q2 revenue beat and higher 2026 guidance

Goodrx is trading 11.16% up now at $3.63 after its August 5, 2026 second-quarter results and August 6 conference call, with a revenue beat and raised guidance.

• Revenue reached $200.4 million; Pharma Direct surged 76% to $61.6 million, supported by manufacturer partnerships and GLP-1 access programs.
• Management raised full-year 2026 revenue guidance to $790–$805 million and Adjusted EBITDA guidance to $240–$250 million.
• Adjusted EPS of $0.08 matched consensus; the broader healthcare sector is also higher.